PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
NCT01209598
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Sarcoma
Liposarcoma
Interventions
DRUG:
Palbociclib 200mg
DRUG:
Palbociclib 125mg
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
[object Object]